144 related articles for article (PubMed ID: 37673116)
1. Rechallenge With Switching Immune Checkpoint Inhibitors Following Autoimmune Myocarditis in a Patient With Lynch Syndrome.
Eslinger C; Walden D; Barry T; Shah S; Samadder NJ; Bekaii-Saab TS
J Natl Compr Canc Netw; 2023 Sep; 21(9):894-899. PubMed ID: 37673116
[TBL] [Abstract][Full Text] [Related]
2. Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report.
Krekeler C; Wethmar K; Mikesch JH; Kerkhoff A; Menck K; Lenz G; Schildhaus HU; Wessolly M; Hoffmann MW; Pascher A; Asmus I; Wardelmann E; Bleckmann A
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569431
[TBL] [Abstract][Full Text] [Related]
3. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
4. A locally advanced colon cancer patient with Muir-Torre syndrome obtains durable response to neoadjuvant and adjuvant immunotherapy.
Guo Z; Cai Y; Yin W; Huang J
Tumori; 2023 Dec; 109(6):NP27-NP31. PubMed ID: 37880978
[TBL] [Abstract][Full Text] [Related]
5. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
6. [A Case of Cholangiocellular Carcinoma in Lynch Syndrome Treated by an Immune Checkpoint Inhibitor].
Shinke G; Takeda Y; Ohmura Y; Katsura Y; Haruna K; Kihara Y; Kusafuka H; Sakaue M; Katsuyama S; Kawai K; Hiraki M; Masuzawa T; Takeno A; Hata T; Murata K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2014-2016. PubMed ID: 35045478
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
8. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
[TBL] [Abstract][Full Text] [Related]
9. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
10. Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.
Kawashima Y; Nishikawa S; Ninomiya H; Yoshida R; Takano N; Oguri T; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ishikawa Y; Nishio M
Intern Med; 2019; 58(10):1479-1484. PubMed ID: 31092773
[TBL] [Abstract][Full Text] [Related]
11. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
12. Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome.
Elze L; van der Post RS; Vos JR; Mensenkamp AR; de Hullu MSC; Nagtegaal ID; Hoogerbrugge N; de Voer RM; Ligtenberg MJL
J Natl Cancer Inst; 2023 Jul; 115(7):853-860. PubMed ID: 37018159
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
14. Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature.
Chinczewski L; Feldhaus FW; Schmitt W; Braicu I; Roser E; Sehouli J
Anticancer Res; 2023 Apr; 43(4):1655-1662. PubMed ID: 36974818
[TBL] [Abstract][Full Text] [Related]
15. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients.
Yu JH; Xiao BY; Tang JH; Li DD; Wang F; Ding Y; Han K; Kong LH; Ling YH; Mei WJ; Hong ZG; Liao LE; Yang WJ; Pan ZZ; Zhang XS; Jiang W; Ding PR
Eur J Cancer; 2023 Oct; 192():113253. PubMed ID: 37625240
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability testing in colorectal patients with Lynch syndrome: lessons learned from a case report and how to avoid such pitfalls.
Adeleke S; Haslam A; Choy A; Diaz-Cano S; Galante JR; Mikropoulos C; Boussios S
Per Med; 2022 Jul; 19(4):277-286. PubMed ID: 35708161
[TBL] [Abstract][Full Text] [Related]
19. Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies.
Kim M; Chang CS; Choi MC; Lee JW; Park H; Joo WD
Yonsei Med J; 2023 Oct; 64(10):587-592. PubMed ID: 37727917
[TBL] [Abstract][Full Text] [Related]
20. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
